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Autism Spectrum Disorder (ASD) is a neurodevelopmental condition 
affecting approximately 1% of the population. It occurs roughly four times more in 
males than females, and includes individuals with classic autism, as well as 
those with “incomplete” forms. Behavioral characteristics include, but are not 
limited to: restricted, stereotyped, and repetitive actions, as well as impairments 
in communication and social interaction.  At the Greenwood Genetics Center, 
Greenwood, SC, ASD patients and control donors provided peripheral blood as a 
source of lymphocytes, and a skin-scrape sample as a source of fibroblasts for 
genetic analysis.  A severely autistic patient, coded as B26, his two parents 
(mother Y17, father VT8), and two donor controls (JOR, RT9) were compared.  
Patient and donor lymphocytes were transformed into immortal lymphoblast lines 
using EBV-transformation procedures.  In addition to routine genetic analysis, 
both fibroblasts and lymphoblasts were evaluated by GGC researchers as a 
possible platform to generate neuronal cells through iPS steps.  Attempts were 
successful with fibroblasts, but not lymphoblasts.  In this thesis, these five 
lymphoblast lines were evaluated for possible association with ASD and both 
parents, along with two donor controls. These cells were also examined for their 
potential in other areas of research, including the autocrine production of 
inflammatory and anti-inflammatory cytokines, reactivation of RAG-1 as a 
consequence of EBV-transformation, pharmacological and toxicological 




tryptophan exposure.   All five cell lines produce significant quantities of the 
autocrine B-cell growth factor IL-6, and, to a lesser degree, IL-10, before and 
after further activation with phorbol ester in combination with calcium ionophore.  
Patient B26 and his two parents produced the most cytokine in response to 
activation, while the control donors had a higher baseline production.  All five 
cells lines expressed RAG-1 protein, indicating reactivation of B-cell receptor 
diversity process that may lead to a different BCR specificity.  In pharmacology 
and toxicology, many xenobiotics and endogenous metabolites of tryptophan act 
through the AHR leading to induction of phase I, II, and III enzymes.  The 
classical marker of AHR activity is the induction of CYP1B1.  In response to 
FICZ, a potent tryptophan intermediate, patient B26 had the highest level of 
CYP1B1 induction, followed by Y17, the mother.   Because tryptophan is 
metabolized by IDO2 in activated normal lymphocytes, the induction of IDO2 was 
quantified after activation with phorbol ester and calcium ionophore.  Expression 
of IDO2 was highest in patent B26, followed by Y17, the mother.  Recent 
research at GGC suggests that tryptophan is metabolized differently in ASD 
patients when compared to donor controls.    A commercially available PCR array 
of genes associated with tryptophan metabolism was then employed and 
revealed that key genes involved in tryptophan metabolism are not altered in the 
severely autistic patient B26, either of B26’s two parents (mother Y17, father 
VT8), nor the two donor controls (JOR, RT9). The array also showed that several 




treatment in B26, and similarly in the mother, Y17. Genes not only involved in 
energy metabolism, but also inflammation and different pathways stemming from 
tryptophan metabolism (serotonin and melatonin pathways) were increased.  
This study shows that lymphoblasts generated from ASD patients and donor 
controls may have use outside of the field of autism research, and may lead to 
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LITERATURE REVIEW 
 ASD is a behavioral syndrome that is usually revealed during early 
childhood and is hypothesized to reflect underlying neurodevelopmental 
abnormalities [1]. Core symptoms of ASD include abnormal or unreciprocated 
interpersonal interactions, muddled language and communication, and repetitive 
and stereotypic behavior [2]. Several biomarkers have been associated with 
ASD, but there are currently no laboratory tests to be used as concrete 
diagnostic tools [3]. The etiology of ASD has brought upon much divisiveness 
among scientists and the general public in recent years. There has been a 
dramatic climb in the number of children diagnosed with one of the ASDs, with 
the most severe form being autistic disorder [4]. In the United States alone, the 
diagnosis of ASD has increased almost ten-fold over the last decade [5]. This 
increase is seen as alarming because in the 1980’s, there were roughly 4-5 
children per 10,000 diagnosed. In the 1990’s, there were about 30-60 children 
diagnosed per 10,000 people [6]. Some scientists believe that a main cause of 
this upsurge is the result of heightened awareness of ASD now compared to the 
1980s. Some believe that it is the change in diagnostic criteria, suggesting that 
the number of people with ASD has stayed stable over time [7]. There are few 
studies that have been designed to definitively address whether the true 
prevalence of ASD has stayed stable or increased during time, but many agree 
that it would be premature to state that there is no increase in prevalence [8]. 




described. Much less research is focused on the causes of these symptoms. This 
begs the question of why - why are the core symptoms of ASD social disinterest, 
problems in communication, and overly focused behavior? Where do these 
behaviors internally stem from? The goal of this literature review is to highlight 
the relevance of prior studies in the development of this thesis as it pertains to 
ASD from a genetic standpoint, as well as cytokine involvement and AhR 
activation in ASD patients. 
A previous study analyzed the metabolic profile of lymphoblast cell lines 
from 137 patients with neurodevelopmental disorders with and without ASD and 
78 control individuals [9]. This and another study looked at individuals with ASD 
versus control patients, and saw that the ASD patients exhibited on average 
reduced generation of NADH when tryptophan was the sole energy source [10]. 
The results correlated with the behavioral traits associated with either syndromal 
or non-syndromal autism, but it did not seem to matter what the genetic 
background of the individual was [11]. A low level of NADH generation in the 
presence of tryptophan was observed in cell lines from ASD patients, but not in 
cell lines from non-ASD patients with either intellectual disability, schizophrenia 
or similar conditions to ASD except for the behavioral traits [12].  
Analysis of a previous small gene expression study found abnormal levels 
for some genes involved in tryptophan metabolic pathways in 10 patients [13]. It 
can be hypothesized that the observed reduction of tryptophan metabolism in 




pathways in the cells [14]. Some of the most frequently reported findings in ASD 
brains are increased brain size and increased white matter [15]. It is possible that 
impairment of the kynurenic pathway may have consequences on the pruning 
process in the brain and lead to an excess of white matter [16]. Microglial cells 
are considered to be responsible for keeping the proper balance between 
quinolinic and kynurenic acid, since they are able to secrete both compounds 
[17]. The expression of those molecules is strongly influenced by the activity of 
the immune system, which has been implicated as impaired in ASD individuals in 
a number of studies.  
Tryptophan is also the main precursor for both melatonin and serotonin. 
Melatonin plays a critical role in the regulation of the circadian rhythm, and 
disturbances in this rhythm have been associated with several symptoms in ASD, 
like seizures or sleep disorders [18]. Serotonin is an important neurotransmitter 
involved in many functions, from the regulation of mood to the control of appetite 
and social interactions, and its production has been reported as deficient in the 
brains of ASD individuals [19]. Since tryptophan levels have been shown to 
influence central nervous system serotonin levels and behavior, it can be 
concluded from these studies that an altered tryptophan transport exists in 
patients with ASD [20]. 
The cell lines studied included a severely autistic child, B26, as well as the 
two parents of the patient with ASD and two donor controls (JOR and RT9). B26 




parent respectively. These microdeletions on the corresponding chromosomes 
have been associated with developmental delay, low muscle tone, and 
communication difficulties, and ASD. It would be advantageous to know how, or 
if, a combination of chromosomal deletions could be linked to the severity of 
ASD, and to look at the evolution of genome sequencing. In the twentieth 
century, knowledge about human genetic variation was limited mainly to the 
heterochromatin polymorphisms, and single nucleotide polymorphisms (SNPs) 
identified by traditional PCR-based DNA sequencing. In the past ten years, the 
swift development and extended use of microarray technologies, such as the 
commercial array used in this study as well as next-generation sequencing, has 
enabled a whole-genome analysis with essentially unlimited resolve [21]. The 
discovery of submicroscopic copy-number variations (CNVs) present in our 
genomes has changed the perspective on DNA structural variation and disease. 
CNVs have been shown to be responsible for susceptibility to traits (genomic 
disorders), genetic diversity, and human evolution. In addition, many common 
complex traits including autism can result from CNVs.  Since CNVs can involve 
part of a gene or even several genes, some CNVs are likely to have a role in the 
alteration of human physiological functions, causing disease [22]. They therefore 
are likely to be subject to evolutionary pressures such as selection and genetic 
drift.  
Altered immune response in ASD individuals has been reported for almost 




brain and CNS based upon specimens obtained from individuals with ASD [24]. 
Several studies have shown immune differences in children with ASD, such as 
abnormal cytokine profiles [25]. A subset of studies have demonstrated 
increased levels of inflammatory cytokines in ASD, such as IL-6 and increased 
levels of IL-10 [26]. However, varied experimental designs, diagnostic criteria, 
varying ages in comparison of ASD patients with donor controls (children with 
ASD vs. adult controls) have caused misinterpretation of the results [27]. Small 
sample sizes have posed a challenge in the ability to detect differences in 
cytokine patterns between ASD patients and donor controls, and this is 
showcased in the current study. 
Lastly, countless studies have indicated that cells from patients with ASD, 
on average, are less capable of utilizing tryptophan as an energy source than 
controls. Although not published yet, a study by Dr. William Baldwin has 
showcased that B26 fibroblasts contain more mitochondria but are insufficient at 
mitochondrial repair and response to oxidative stress. This is shown through an 
array of important genes in tryptophan metabolism. Moreover, findings in these 
studies were consistent in patients across the autism spectrum and was not 
influenced by age or sex. Decreased tryptophan metabolism in patients with 
ASDs may alter metabolic pathways involved in the regulation of the early stages 
of brain development, mitochondrial homeostasis and immune system activity in 






Autism Spectrum Disorder (ASD) is a neurodevelopmental condition 
affecting approximately 1% of the population. It occurs roughly four times more 
likely in males than females, and includes individuals with classic autism, as well 
as those with “incomplete” forms of autism [29]. People with ASD fall on a 
spectrum between low functioning and high functioning, and the severity ranges 
from patient to patient. Behavioral characteristics include, but are not limited to: 
restricted, stereotyped, and repetitive actions, as well as impairments in 
communication and social interaction. A strong genetic predisposition for ASDs 
has been inferred from a higher concordance in identical twins (between 30%-
60%), as compared to fraternal twins (roughly 6%) [30]. The higher concordance 
rate found in identical twins suggests that multiple genes are related to the cause 
of autism. The combination of affected genes and the environment both play a 
role in the development of ASD. There is no particular laboratory test to diagnose 
ASD, although several biomarkers have been associated with it [31]. The cause 
of ASD is not known and likely involves interactions between environmental, and 
most importantly, genetic factors. 
Links to environmental factors in the development of ASD focus on 
contaminants involved in air pollution, and especially persistent organic pollutants 
(POPs). This includes PCBs, dioxins, and furans, as well as some polycyclic 
aromatic hydrocarbons, such as benzo-a-pyrene, which is also found in 




pollutants are ligands for the aryl hydrocarbon receptor (AHR), a ligand activated 
transcription factor that leads to the induction of phase I xenobiotic metabolizing 
enzymes, such as CYP1B1 and CYP1A1 [33].  While no studies have linked the 
expression of, or genetic variants of AHR with causes of autism, and no studies 
have shown differences between AHR expression and variants in control vs. 
patients, there is a correlation between expression and severity score [34].  One 
of the most potent of AHR ligands is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
and exposure is associated with a plethora of syndromes, including wasting, 
hepatocellular carcinoma, chloracne, reproductive toxicity, thymic atrophy, and 
immune dysfunction; the underlying mechanism may be the loss of NAD+ [35].  
In some ASD patients, altered tryptophan metabolism also leads to the loss of 
NAD+ [36], which may hint to altered AHR signaling in some ASD patients.  
Moreover, the induction of CYP1B1 and CYP1A1 by some environmental 
pollutants may lead to extremely toxic, mutagenic, and teratogenic intermediate 
metabolites.  To date, little is known about the role of AHR, phase I enzyme 
activities, and ASD.   
The expression of CYP1B1 can be induced by a number of endogenous 
ligands, including tryptophan and its metabolites through the AHR [37] [38].   In 
addition, CYP1B1 is involved in the metabolism of many important physiological 
compounds including arachidonic acid, estrogen, melatonin and retinoids [39]. In 
previous research, genes that are known to be involved in tryptophan 




ASD. It was found that these patients expressed CYP1B1 at higher levels than 
those without autism. A previous study done by Smerdova et al. demonstrated 
that there was an upregulation of CYP1B1 expression in ASD individuals 
because of an increase in inflammatory cytokines and aryl hydrocarbon ligands 
[40]. 
Recent papers have described links between genes that encode for 
immune-related proteins such as IL-6 and IL- 10 and ASD, suggesting that 
abnormalities in the immune system may impair brain development [41].  
Interleukin-6 was originally labeled B-cell growth factor because it is critical to the 
growth and proliferation of myeloma cells, but is also known as a classical 
marker of macrophage-associated inflammation, and known to be required for 
normal neurological development and physiology [42, 43]. Intereukin-6 is of 
interest because studies have suggested that brain IL-6 is an important mediator 
of autism-like behaviors [44] [45].  
Current evidence dictates that IL-6 may have a crucial role within the 
CNS. In the CNS, IL-6 can trigger cellular responses such as inflammation, cell 
growth, neurogenesis, and cell survival among other processes [46]. IL-6 is 
ordinarily expressed at reasonably low levels in the brain, but in the presence of 
injury or inflammation, IL-6 is elevated in spinal fluid as well as brain 
homogenate. In a study done by Wei, H. et al., it was shown that chronic 
overexpression of IL-6 in mice causes anatomical and physiological changes in 




Interleukin-10 (IL-10) is a well-known anti-inflammatory cytokine that plays 
an important role in preventing inflammatory pathologies [48]. Gerber et al. found 
that an increase in cathepsin D, a protease abundantly expressed in the brain, 
can trigger secretion of cytokines, including IL-10 due to a corresponding 
increase in pro-inflammatory cytokines, such as IL-6 [49]. This could suggest that 
IL-10 acts in a negative feedback loop, or a homeostasis, for when levels of IL-6 
increase. 
Some research suggests that patients along the ASD scale have an 
altered ability to utilize tryptophan [50]. Tryptophan is an essential amino acid 
and needs to be supplemented via diet. It is also an AhR agonist and precursor 
of many important compounds such as kynurenic acid, serotonin, and quinolinic 
acid – all of which are involved in neurodevelopment and the formation of 
synapses [51].  
The majority of tryptophan is metabolized along the kynurenine-quinolinic 
pathway of tryptophan degradation, and follows two other major pathways of 
metabolism in the GI tract: transformation by microbiota in the gut of tryptophan 
into ligands of the aryl hydrocarbon receptor (AhR), and the serotonin production 
pathway [52]. This is demonstrated in illustration 1. Decreased tryptophan 
production seen in ASD individuals may alter development of the brain, immune 
activity, and mitochondrial function. Studies have shown that the abnormal 
utilization of tryptophan as an energy source further supports possible 




Metabolism of tryptophan via the kynurenine-quinolinic pathway leads to 
the synthesis of NAD+, while the serotonin branch of the tryptophan metabolic 
pathway generates NADH. Serotonin functions as a key neurotransmitter and 
serves as a communication system between the central nervous system and the 
GI tract [54]. The microbial impact on the metabolism of tryptophan and the 
serotonin pathway may be important in the regulation of the brain-gut axis. It has 
been previously concluded that individuals with ASD may have a decreased 
diversity of gut microbiota, dictating serotonin-related health problems [55]. This 
could be related to the ability of the microbiota in the gut to control metabolism of 
tryptophan along the kynurenine pathway, therefore reducing the amount of 
tryptophan needed for serotonin synthesis. 
Observing decreased levels of NADH generation in the presence of 
tryptophan may indicate reduced utilization of tryptophan resulting from 
downregulation of metabolic reactions at any point along the two pathways. The 
kynurenines produced during the kynurenine-quinolinic pathway via indoleamine 
2,3-dioxygenase 2 are potent ligands for the AhR, and are involved mainly in 
inflammatory response, immune response, and excitatory neurotransmission 
[56].  Indoleaminedioxygenases 1 & II (IDO1, IDO2) are induced by various pro‐
inflammatory cytokines (such as IL-6). Therefore, in immune‐activated 
environments, IDO may break down a large proportion of tryptophan leading to a 
shortage for the serotonin–melatonin pathway. It has been observed that in some 




kynurenine-quinolinic pathway and the serotonin pathway compared to donor 
controls, namely the production of IL-6 [57]. 
As previously mentioned, a portion of tryptophan is metabolized in the GI 
tract and transformed by microbiota in the gut into ligands of the AHR. Since the 
AHR contains a promiscuous ligand-binding pocket, it can bind multiple classes 
of exogenous compounds. The photo-oxidation product of tryptophan, 6-
formylindolo(3,2-b) carbazole, otherwise known as FICZ, is one of the more 
potent endogenous ligands for the AHR and may be the primary metabolite of 
indole-3-carbinol (I3C) during digestion, which has been found to modulate the 
expression and activity of biotransformation enzymes involved in metabolism and 
excretion of many biologically active compounds [58]. In addition, FICZ induces 
AHR translocation to the nucleus and transcription of the AHR target gene 
CYP1B1, as demonstrated in illustration 2. Polymorphisms of some AHR-induced 
genes in ASD individuals may cause an increase in CYP1B1 production, 
therefore a possible increase in severity of ASD [59].  The expression of 
indoleamine dioxygenases (IDO) is involved in catabolism of tryptophan and is 
believed to be a major source of tryptophan dysfunction in ASD patients. In other 
studies, it is hypothesized that there is an increased level of IDO, resulting in an 
increased catabolism of tryptophan [60]. This means that tryptophan is possibly 
metabolized too quickly and being delegated to the AHR rather than other 





While progress in ASD research has been made, where studies have 
attempted to evaluate whether cytokine levels are associated with onset of 
stereotypical behaviors in ASD, there are still many shortcomings in finding a 
definitive diagnostic tool in a clinical setting for a concrete diagnosis. As of now, 
there are no laboratory tests that can accurately diagnose ASD. Therefore, 
diagnosis is based upon observed stereotypical behaviors associated with ASD. 
Many children are not diagnosed until the age of 2 or 3, meaning that the window 
to intervene early is essentially closed before a diagnosis is even made [61].  
Researchers at the Greenwood Genetics Center, Greenwood SC USA, 
are intensely focused on autism research.   As part of a larger, long term study, 
ASD patients and control donors have provided peripheral blood as a source of 
lymphocytes, and a skin-scrape sample as a source of fibroblasts, both for 
genetic analysis.  Patient and donor lymphocytes were transformed into immortal 
lymphoblast lines using EBV-transformation procedures.   In addition to routine 
genetic analysis, both fibroblasts and lymphoblasts were evaluated by GGC 
researchers as a possible platform to generate neuronal cells through iPS steps.  
Attempts were successful with fibroblasts, but not lymphoblasts.  However, these 
lymphoblasts lines from ASD patients and donor controls may hold promise in 
aspects of autism research outside of iPS-derived neuronal cells, or even outside 
of autism research. 
EBV-transformed B-cells to lymphoblasts are known to secrete IL-6 in an 




increased by further activation with phorbol esters (e.g., phorbol ester myristate – 
PMA).  It is now known that activiation can be improved by the addition of 
calcium ionophore (e.g., A23187, ionomycin), and this combination is routinely 
used in current research protocols.  The addition of PMA activates 
Calcium/phospholipid-dependent PKC, and calcium ionophore A23187 increases 
intracytosolic free calcium concentration [63].   Together, PMA and A23187 
bypass the early activation pathways and promote B‐cell growth through the 
direct induction of membrane IL‐6 receptor expression and IL‐6 synthesis and 
secretion.  Also, EBV-lymphoblast-derived IL-6 has been used as a source to 
stimulate the growth of human myeloma cells.   These cells also secrete IL-10 as 
a negative control against over stimulation by IL-6 [64].   It has been observed 
that in some, but not all EBV-transformed lymphoblast lines, that RAG-1/RAG-2 
genes are reactivated in terminally activated lines from continuous culture, and 
may be an indication of full activation [65].    
Little is known about the AHR activities in EBV-derived lymphoblasts, 
including baseline AHR expression levels and induction of CYP1B1 by AHR 
ligands, but one study showed that AHR activation leads to EBV-reactivation in 
latent infected B-cells, which may lead to Sjogren’s Syndrome [66]. The 
questions of how do EBV-transformed lymphoblasts respond to AHR ligands is 
an open question, and fertile ground for future research.  Moreover, this is even 




To my knowledge there is no consensus on how tryptophan is 
metabolized by EBV-transformed B-cells in general, but metabolism of this 
critical amino acid during other chronic viral diseases has been examined [67].  
Tryptophan depletion by IDO and AHR both depletes tryptophan needed by the 
pathogen, and contributes to the state of local immunosuppression induced by 
metabolites, because prolonged activation of the AHR leads to 
immunosuppression [67].  Whether or not tryptophan metabolism in chronically 
activated EBV-transformed lymphoblasts from a severe ASD patient is different 
than donor controls is one of the key questions asked in my thesis.   
The purpose of the research for this thesis is to characterize lymphoblasts 
cell lines derived from ASD patients and control donors to determine if there are 
intrinsic differences in levels of secretion of autocrine growth factors IL-6 and IL-
10, in states if activation, expression of AHR and CYP1B1 involved in the 
metabolism of endogenous indoles, and differences in gene expression 
pathways involved in tryptophan metabolism.  A severely autistic patient, coded 
as B26, his two parents (mother Y17, father VT8), and two donor controls (JOR, 
RT9) were compared.  It is my hope that this information will be a spring board 
for the next set of approaches using these cell lines, and for the development of 
possible screening biomarkers for differences between ASD patients and those 








 First, peripheral blood lymphocytes from ASD patients and donor controls 
were provided to Greenwood Genetics Center and transformed to immortal B-cell 
lymphoid cell lines using EBV transformation. Cells from each subject were 
coded by internal referencing numbers, and later given an abbreviated name. 
This study focuses on one patient with severe ASD having deletions 10p12.31 
and 15q15.3, inherited from the mother and father, respectively. The patient with 
ASD was given the code B26. The patient’s parents were given code Y17 
(mother) and VT8 (father), and the other two donor controls were coded RT9 and 
JOR. 
The following general procedure for transforming B-cells to lymphoblast is 
as follows.  First, mL of blood was drawn from each donor and diluted with 20 mL 
of PBS at room temperature. The diluted blood was subsequently put into 
separation media and centrifuged at 225 x g at room temperature for 30 minutes. 
Concentrated white blood cells that collected at the top were removed, and the 
sample was diluted with PBS up to 50 mL.  Samples were spun down once more 
at 600 x g at room temperature for 10 minutes. After centrifugation, supernatant 
was poured off, and the cells were washed by re-suspending the pellet in 50 mL 
PBS, and spinning down at the same settings. This was repeated twice more. 
Once the cells were washed, they were re-suspended in 1 mL of fresh media. 




 Infection with EBV 
Methods for transforming B-cells followed previously published methods 
[68, 69], and carried out by researchers at the Greenwood Genetics Center 
(GGC), Greenwood, SC USA.  Exponentially growing B95-8 cells (ATCC # CRL 
1612; 13) at 3 x 105 cells/ml in a 75cm2 tissue culture flask were maintained 
using sterile technique. Cells are grown in complete RPMI 1640 containing 10% 
heat-inactivated fetal bovine serum (FBS), Penicillin/Streptomycin at 100U/ml 
and 100 μg/ml, respectively, and Amphotericin B at 0.5 μg/ml at 37°C in the 
presence of 5% CO2. To ensure virus production, the cells were stimulated with 
20ng/mL tetradecanoyl phorbol acetate (TPA; a.k.a. PMA) for 1 hour in a 
standard CO₂ incubator. The cells were then washed three times with the media 
to remove the TPA. Cells were re-suspended in the same amount of fresh media 
previously mentioned and placed in a flask inside of the incubator for 96 hours. 
After the incubation time, cells were centrifuged at 600 x g in order to separate 
the supernatant containing EBV. The supernatant containing virus was then 
filtered out through a 0.45 µn filter, partitioned, and stored at -70°C. Peripheral 
blood cells from patients and donors were mixed with virus-containing 
supernatants as previously described, and stimulated with phyohemmaglutin-A 
(PHA).  FK506, a T cell immunosuppressant, was added to the cell suspension 
from above, and placed into the incubator at 37°C for 1 hour. After incubation, an 
aliquot of EBV previously prepared was added to the flask at a 1/10 dilution. The 




subsequently cloned and verified to be B-cell blast using flow cytometry with B-
cell-specific antibody markers.   
 Both the ASD and donor control human lymphocyte cell lines were stored 
at GGC, and also maintained at Clemson University.  Cells are grown in 
Dulbecco’s modified Eagle’s medium (DMEM; Corning) supplemented with 20% 
heat inactivated fetal calf serum (Thermo Fisher), 25mM HEPES, 4.5 g/L 
glucose, 110 µg/mL sodium pyruvate, 10 mM L-glutamate, 100 U/mL penicillin, 
100 µg/mL streptomycin, 20 mg/mL Gentamicin, 10 mg/mL Nystatin, 1% MEM 
Non-Essential Amino Acids (100X), and 7.5% sodium bicarbonate, each from 
Sigma (Sigma Aldrich, St. Louis MO, USA). Cells were grown and maintained at 
37°C in a standard incubator in 75 cm² culture flasks. 
 
Expression of IL-6 and IL-10 in untreated and stimulated cell lines  
Cell lines were maintained prior to manipulation as described above. Two 
separate conditions were investigated. In the first set or experiments, cells were 
seeded at 2 x 10⁶ cells/mL in T-25 cm² Corning culture flasks, in triplicate, and 
supernatants collected at the start of culture, and again at 6 and 12 hr to 
determine baseline production of IL-6 and IL-10. This was to determine the 
relative rate of production by each line, but also to determine the relative 
magnitude of production.  In the second set of experiments, the same culture 
conditions were maintained, except that each cell line was treated with either 




M A23187, which bypasses the B-cell receptor signaling pathways to activate 
PKC-delta, NFK-beta, and AP-1 to stimulate production of cytokines. IL-6 and IL-
10 were both quantified by Human IL-6 ELISA MAX Deluxe Set (Biolegend) and 
Human IL-10 ELISA MAX Deluxe Set (Biolegend) respectively, following 
directions provided by the supplier. 
 
Expression of RAG-1 and AHR protein 
Two million lymphoblasts were seeded in T-25 flasks in 3 ml of media and 
incubated for 24 hr. Cells were removed from each flask and pelleted by 
centrifugation and covered with 500 μl RIPA lysis buffer (50 mM Tris HCl, pH 8, 
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) 
containing protease inhibitor cocktail (Pierce). The cell pellet was disrupted by 
gentle vortexing, and incubated on ice for 30 min. Thirty micrograms of whole cell 
lysate protein from each sample were separated by SDS-PAGE on 4-20% gels 
(Biorad) and transferred overnight onto 0.2 PDVF membranes (Thermofisher) at 
4 °C.  For RAG-1 detection, whole mouse thymus lysate (Novus Biologicals) was 
examined as a positive control.   For AHR detection, cell lysates from the human 
glioblastoma cell line T98G (ATCC) were used due to the high amount of AHR 
expressed in these cells [70].  The membranes were washed three times with 
0.01 M phosphate buffered saline (PBS) containing 0.1% tween-20 (PBS-tw20), 
covered with blocking buffer (10% FCS in PBS) for 1 h and again washed three 




anti-human RAG-1 antibody (RNF4; Abcam) at 2 ug/ml, mouse monoclonal anti-
humann AHR (mAb A-3; Santa Cruz) at 2 ug/ml, or mouse monoclonal anti-β 
actin (Sigma Aldrich) at 2 ug/ml.  Antibodies were diluted in PBS-tw20 containing 
1% FCS. The blots were washed three times for 10 min with PBS-tw20, and 
probed for 2 h with either goat anti-rabbit IgG, or goat anti-mouse IgG secondary 
antibody conjugated with alkaline phosphatase (ThermoFisher) diluted 1:1000 in 
PBS-tw20 containing 1% FCS. After extensive washings with PBS-tw20, alkaline 
phosphatase activity was determined using the substrate NBT-BCIP to visualize 
the relative amount of specific protein. 
 
Expression of CYP1B1 and IDO2 mRNA 
To quantify CYP1B1 and IDO2 mRNA expression, each cell line was 
cultured in T-24 cm3 flasks as described above, and treated with 10 nM FICZ (for 
CYP1B1 expression), or 1 uM PMA + 0.5 M A23187, (for IDO2 expression) for 12 
hr.  PMA + A23187 by passes the B-cell receptor signaling pathways to activate 
PKC-delta, NFK-beta, and AP-1 to stimulate IDO2 expression. The treatments 
were done in triplicate for each cell line. Following the treatment regimen, each 
sample was centrifuged, and a pellet was formed from each of the three 
replicated experiments.  RNAzol (Molecular Research) was added (1 mL) to cell 
pellets, and the mixture was homogenized by pipetting gently several times. 
Samples were stored at -4°C until ready to use. Total RNA was isolated using 




out using the RT² Easy First Strand Kit (SABioscience Corporation) as outlined 
by the manufacturer. Gene expression was evaluated by quantitative PCR with a 
BioRad iC5 detection system, RT² SYBR green master mix, and primer sets 
designed using Integrated DNA technology software. The primer sets were 
validated prior to use, and the quantity of mRNAs was expressed as fold 
changes using GAPDH as a housekeeping gene.  Primer sets and relative 
information are as below.
. 
Table 1. Primer sets for quantifying CYP1B1 and IDO2 induction 
 
 
For data analysis, the ΔΔCt method was used, and data was compared between 
treatments using ANOVA. 
 
Commercial qPCR array for genes involved in tryptophan metabolism 
Lymphoblastoid cells were seeded at 2 x 10⁶ cells/mL in 75 cm² Corning 
culture flasks. Cells were then treated for 24 h with 2 mM tryptophan as 
recommended by others [71]. This experimental regimen was repeated three 
times and the lymphocytes were pooled (n = 3) per treatment regimen, then 




replicated experiments. One milliliter of TRI-reagent® (Molecular Research) was 
added to cell pellets and the mixture was homogenized by gently pipetting 
several times. The homogenate was incubated at room temperature for 5 min 
and 0.2 mL chloroform was added. Total RNA was then isolated via 
manufacturer instruction. After collecting RNA from each tube, DNA 
contamination was removed using an elimination mixture supplied by the 
manufacturer, and first strand cDNA synthesis was carried out using the RT2 
Easy First Strand Kit (SABioscience Corporation) as described by the 
manufacturer. A predesigned Amino Acid Metabolism ProfilerTM array of 96 
genes was purchased from SuperArray Bioscience Corporation for use with RT2 
Real-Timer SYBR Green/ fluorescein qPCR master mixes purchased from the 
same supplier. Specific methods followed those suggested by the manufacturer. 
QPCR was performed on a BioRad iQ5 real-time PCR detection system. For 
data analysis, the ΔΔCt method was used; for each gene, fold-changes were 
calculated as difference in gene expression between untreated controls and 
treated cell cultures. Data were gathered and interpreted using software provided 
by SABioscience. The goal was to determine which genes may be of interest to 







IL-6 and IL-10 expression in untreated cell lines, and cell stimulated with PMA + 
A23187 
Interleukin-6 secretion in lymphoblast lines was compared to background 
levels in complete media, and shown vary from line to line, but was higher in both 
control donors than in B26 and the two parents (Figure 1A).  This was the case 
for both 6 hr and 12 hr incubation.   Under these conditions donor JOR produced 
the most IL-6, followed by donor RT9.  Interleukin-10 secretion by lymphoblasts 
under the same culturing conditions was higher than IL-6, with the two donor 
controls secreting the most (Figure 1B).  At 6r, IL-10 secretion by VT8 (the father) 
was also high, and nearly matched the two donor lines. By 12 hr, IL-10 levels in 
the father’s line (VT8) were lower, as were the others. 
 
Figure 1.  Interleuking-6 and IL-10 secretion by lymphoblast cell lines at 6 hr and 




treatment.  Cytokine levels were quantified by ELISA, and the data represent the 
mean +/- S.E. of levels above that measured in complete media without cells. 
 In response to PMA + A23187, IL-6 and IL-10 secretion was quantified as 
an indicator of the ability of lymphoblast to increase production beyond 
background.  Cells generated from patient B26 responded with a robust increase 
in secretion of IL-6 secretion at 12 (Figure 2A), with the expected increase over 
time.  Likewise, Y17 cells (the mother) responded to stimulation with a large 
increase in production over time (Figure 2B).  This was also observed in VT8 
cells (the father) in response to stimulation over time (Figure 2C).  Cells derived 
from the two donor controls did not respond as well as the other three, with RT9 
producing a modest amount at 6 hr, and much less at 12 hr (Figure 2D), while 
donor JOR produced very little IL-6 at 6r, and nothing significant at 12 hr (Figure 
2E).  These observations are nearly reversed of what was produced by 























Figure 2.   Interleuking-6 secretion by lymphoblast cell lines at 6 hr and 12 hr 
culture after stimulation with PMA + A23187.  Cytokine levels were quantified by 
ELISA, and the data represent levels above non-stimulated cells.  Data represent 
the mean +/- S.E. of fold increase above baseline secretion in three separate 
experiments. *** = p < .001, * = p < .05. 
 Interleukin-10 secretion by B26 cells was increased significantly at 6r and 
12 hr, but the levels at 12 hr were less than at 6 hr (Figure 3A).  Similar 
responses were observed in Y17 cells (Figure 3B), though the magnitude was 
less than that of B26.  Responses to stimulation in VT8 cells were higher at 6 hr, 
but not 12 hr (Figure 3C).  For RT9 cells, IL-10 secretion was significantly 




with IL-6 production in response to stimulation, JOR cells produced very low 
levels of IL10 upon stimulation (Figure 3E). 
 
Figure 3.  Interleuking-10 secretion by lymphoblast cell lines at 6 hr and 12 hr 
culture after stimulation with PMA + A23187.  Cytokine levels were quantified by 
ELISA, and the data represent levels above non-stimulated cells.  Data represent 
the mean +/- S.E. of fold increase above baseline secretion in three separate 
experiments. *** = p < .001, ** = p < .01. 
 
Expression of RAG-1 and AHR in lymphoblast cell lines 
Cellular expression of recombination activation gene-1, RAG-1, evident in 




high as can be seen in the mouse thymocyte lysate (Thy), and all bands were at 











Figure 4.  Expression of RAG-1 protein in whole cell lysates from lymphoblast 
cell lines.  Thirty ug of lysate protein were subjected to SDS-PAGE and 
immunoblotting using a RAG-1-specific antibody.  Equal amounts of protein were 
subjected SDS-PAGE and immunoblotting using a β-actin specific antibody.  
Whole mouse thymus tissue lysates (Thy) were used as a positive control for 
RAG-1 
Cellular expression of the AHR was evident in all 5 cell lines, with a slight 
reduction in the Y17, and perhaps VT8 (Figure 5, Figure 6).  These proteins were 
of the expected molecular weight of approximately 100 kDa, and were expressed 














Figure 5.  Expression of AHR protein in whole cell lysates from lymphoblast cell 
lines.  Thirty ug of lysate protein were subjected to SDS-PAGE and 
immunoblotting using a AHR-specific antibody.  Equal amounts of protein were 
subjected SDS-PAGE and immunoblotting using a β-actin specific antibody.  





















Figure 6.  Band density of AHR expression in lymphoblasts.  Bands density was 
determined using Image J software (NIH).   
 
CYP1B1 and IDO2 expression as markers for the trypto-AHR pathway 
 In response to the endogenous AHR ligand FICZ, CYP1B1 induction was 
highest in B26 cells, and was significantly higher than the other four cells lines 
(Figure 6A).  When examining for differences in CYP1B1 mRNA levels between 
all pair-wise comparisons, there we no differences between the V17, VT8, JOR, 
and RT9.  Expression levels in VT8, JOR, and RT9 were roughly two-fold, with 





 In response to PMA + A2317 as a means to activate the cells to induce 
expression of IDO2, B26 cells responded more than the other four cell lines 
(Figure 6B).  When examining for differences in IDO2 mRNA levels between all 
pair-wise comparisons, there we no differences between the V17, VT8, JOR, and 
RT9.  Expression levels in Y17, VT8, JOR, and RT9 were roughly 3 – 4 fold, with 
B26 cell expressing nearly twice that level. 









Figure 7.  CYP1B1 mRNA induction in lymphoblast cells lines following 12 hr 
treatment with FICZ (A).  IDO2 mRNA induction in lymphoblast cells lines 
following 12 hr treatment with PMA + A23187 (B).  Data represent the mean +/- 
S.E. of fold increase over GAPDH mRNA expression in three separate 
experiments.  *** represent p < .001.   
 




 A commercially available qPCR array platform for evaluating tryptophan 
metabolism was used as a screening approach to determine if treatment with 
tryptophan modulates changes in mRNA expression of genes involved in 
tryptophan metabolism in the lymphoblasts. The data provides an indication of 
relative magnitude of expression compared to DMSO controls and allows 
observation of relative changes in gene expression associated with inflammation, 
apoptosis, cell cycle control, and oxidative stress. Under these conditions, some 
of the lymphoblasts exhibit an increased expression of several mRNAs 
associated with activation, signaling, pro-inflammatory, and catabolism of 
tryptophan available on this array (Figure 1). For each mRNA evaluated on the 
array, treatment either decreased expression (more than 2-fold suppression), 
had no effect, or only slightly increased (2-fold or higher). Of note, B26 was the 
very high expresser for some genes involved in energy conversion/metabolism, 
melatonin synthesis, and genes involved biosynthesis of arginine (ACADM, 
AANAT, ACAT1, ACMSD, ALDH18A1, ARG2, ASL, and BHMT). For B26, all of 
these genes were significantly expressed (>10-fold). It can be noted that both 
Y17 and VT8, the parents of B26, had some of the same significant increases in 
some genes similar to B26, namely ACADM, ACAT1, ALDH18A1. Several 



























Table 2 shows an array outlining fold change in genes involved in tryptophan 









Gene name Genbank # Symbol B26 VT8 Y17 JOR F34 PO1 T48 GN12
Aminoadipate aminotransferase NM_016228  AADAT -1.70 -1.70 1.39 1.75 1.91 4.75 7.53 -1.55
Aralkylamine N-acetyltransferase NM_001088 AANAT 17.13 10.87 1.03 -3.87 2.95 1.15 8.30 2.31
Acyl-CoA dehydrogenase medium chain NM_000016 ACADM 13746.90 2947.08 -1.17 2.44 2.37 136.42 848.69 1.66
Acetyl-CoA acetyltransferase 1 NM_000019 ACAT1 140.28 19.32 -1.19 2.51 1.64 3.56 23.93 1.59
Aminocarboxymuconate semialdehyde decarboxylase NM_138326 ACMSD 12.93 2.51 -5.36 -2.38 6.49 -1.68 12.29 1.48
Aldehyde dehydrogenase 9, family member A1 NM_000696 ALDH9A1 3.52 1.45 -1.07 -1.26 1.59 2.34 21.18 1.32
Aldehyde dehydrogenase 18, family member A1 NM_002860 ALDH18A1 11.83 11.24 -2.28 3.11 3.75 24.90 23.21 1.14
Amine oxidase, Cu containing 1 NM_001091 AOC1 -1.70 -1.70 1.39 45.14 1.91 1.92 -1.41 -1.55
Aldehyde oxidase 1 NM_001159 AOX1 -1.70 -3.85 1.39 1.28 -2.09 1.92 -1.41 -1.55
Arginase 2 NM_001172 ARG2 12.10 3.73 -1.07 1.53 1.88 -1.26 6.51 1.43
Argininosuccinate lyase NM_000048 ASL 17.25 3.70 -1.22 1.28 1.88 -1.28 5.40 1.10
Betaine-homocysteine S-methyltransferase NM_001713 BHMT 24.51 -1.60 -17.29 1.64 1.75 1.92 4.10 10.78
Catalase NM_001752 CAT 1.61 -1.02 -1.48 -1.29 2.12 -2.31 4.26 1.15
CYP1B1 NM_000104 CYP1B1 7.58 5.56 -1.06 -3.34 -2.05 1.83 29.25 2.58
DOPA decarboxylase NM_000790 DDC 1.06 -2.06 1.41 1.09 -1.42 3.88 -1.41 1.89
Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase NM_001966 EHHADH 2.78 -4.13 -1.05 -1.27 2.48 3.03 7.43 1.57
Glutaryl-CoA dehydrogenase NM_000159 GCDH 2.19 1.08 -1.05 1.51 1.49 -1.50 1.44 -1.02
3-hydroxyanthranilate 3,4-dioxygenase NM_012205 HAAO 1.10 1.07 -1.49 1.52 1.28 -1.42 2.10 1.39
Indoleamine 2,3-dioxygenase 1 NM_002164 IDO1 -10.35 -1.70 1.39 -5.62 1.91 1.92 5.32 -1.55
Indolethylamine N-methyltransferase NM_006774 INMT 2.39 -1.70 -7.24 -1.06 1.91 1.92 -6.46 -4.06
Kynurenine 3-monooxygenase NM_003679 KMO 1.02 1.28 -3.92 -1.28 1.54 -2.12 2.75 -1.12
Kynureninase NM_003937 KYNU 1.56 1.51 -3.12 1.36 1.03 -2.47 3.85 1.03
Monoamine oxidase B NM_000898 MAOB -1.70 -1.70 1.39 -1.70 1.91 1.92 -1.41 -1.55
Nitrilase family member 2 NM_020202 NIT2 1.53 1.45 -1.82 -1.70 -1.48 -1.60 29.33 2.39
Oxoglutarate dehydrogenase like NM_018245 OGDHL -1.16 1.68 2.24 -1.70 -1.19 2.31 1.02 -1.22
Tryptophan 2,3-dioxygenase 2 NM_005651 TDO2 -2.18 -1.70 1.39 -1.70 4.28 1.92 1.80 -1.55
Tryptophan hydroxylase 2 NM_173353 TPH2 -1.70 -1.70 -2.31 1.05 1.91 1.92 -1.41 -1.07





In this study I found that lymphoblasts from ASD patient B26 stand out from the 
other 4 cell lines and may provide a wealth of information in the fields of 
inflammation, AHR biology, toxicology, mitochondrial functions, and possibly 
others, including ASD.  This cell line secretes low basal levels of IL-6 compared 
to other lines but responded very well to stimulation with PMA + A23187 by 
secreting more IL-6 than the other lines.  This observation suggests that PKC, 
NFkB, AP-1 and other signaling components are intact. Though not examined in 
this study, studies examining fibroblast mitochondrial numbers are much higher 
in B26 than the other lines, and if this holds true for B26 lymphoblasts, then that 
may explain the rapid growth of this line compared to the others.  The control 
donor cells secreted high background levels of IL-6 in comparison to B26 and his 
two parents, and may be useful in generating IL-6 supernatants to support 
hybridomas during the production of monoclonal antibodies, since mouse cells 
respond to human IL-6 [72].   The high levels of CYP1B1 induction by the 
endogenous AHR ligand FICZ suggests that AHR signaling in B26 cells is not 
altered by the EBV-transformation process, and this cell line may prove useful in 
future studies examining AHR biology.  This study can draw no conclusions that 
would suggest the other 4 cell lines have impaired AHR signaling, but a few of 
the lines expressed less AHR protein than did B26.  All 5 lines expressed levels 
of RAG-1 comparable to fresh mouse thymocytes, which are a rich source of 




transformation process.  During normal B-cell development, RAG-1 (and RAG-2) 
are expressed at two key check points to generate a functional heavy chain, 
followed by the generation of a functional light chain, then the expression is 
turned off in a mature B-cell.  It may be that the transformation process drives the 
B-cell back towards a pre-B-cell stage in which RAG-1 is re-expressed.   RAG-1 
may also be re-expressed during receptor editing when B-cell has the opportunity 
to generate a new light chain if the original light chain recognizes “self”.  These 
cell lines may provide a model for RAG-1 genetics. To my knowledge, there is no 
relationship between RAG-1 expression and ASD. 
In this study it was found that key genes involved in tryptophan 
metabolism are not altered in patient B26, either of its parents, nor the two donor 
controls.  The mother of B26, VT8, was likewise responsive to tryptophan in 
terms of CYP1B1 induction. The array data shows that several genes involved in 
mitochondrial function were very responsive to tryptophan treatment in B26, and 
similarly in the mother, Y 17. Genes not only involved in energy metabolism, but 
also inflammation and different pathways stemming from tryptophan metabolism 
(serotonin and melatonin pathways) were affected.  Although not yet published, 
studies in Dr. William Baldwin’s lab at Clemson University show that fibroblasts 
from B26 have very high numbers of mitochondria compared to other patients 
and donors, but B26 fibroblasts did not demonstrate ample repair mechanisms 
during hydrogen peroxide oxidative stress associated with mitochondria, and 




 CYP1B1 and IDO2 are two genes expressed in tryptophan metabolism 
pathways, though the commercial array did not have IDO2 as one of the primer 
sets. CYP1B1 is expressed when the AHR is activated, as seen with treatment 
with FICZ in the qPCR experiments – FICZ us a potent endogenous ligand for 
the AHR.  IDO2 is expressed during the catabolism of tryptophan in a variety of 
tissues, and especially activated lymphocytes, leading to the formation of 
intermediate metabolites, several of which are known ligands for the AHR.  An 
increase in these two genes in ASD individuals could point to a dysfunctional 
metabolism of tryptophan and its metabolites.  Only one severely autistic patient 
is represented in my study, but CYP1B1 and IDO2 may be expressed at higher 
levels in people with ASD because tryptophan is broken down rapidly, therefore 
favoring the AHR and being infrequently utilized in other pathways, such as the 
serotonin pathway. Kynurenine plays an important role in preventing autoimmune 
responses by generating regulatory T-cells through the activation of AHR.  In 
ASD, it seems that tryptophan is directed away from the kynurenine pathway and 
results in a decreased production of kynurenine [73]. Low kynurenine is 
associated with a lower than normal regulatory T- cell production (Treg) and a 
higher risk of developing autoimmunity. This is demonstrated by the increased 
catabolism of tryptophan in ASD patients compared to donor controls.  However, 
there is no current evidence that ASD is an autoimmune disease, but there may 




 There is no rapid laboratory test to diagnose ASD, although several 
biomarkers have been associated with it – namely altered tryptophan 
metabolism. My study may provide a few biomarkers, such as B-cell activation by 
PMA + A23187, peripheral lymphocyte CYP1B1 induction by FICZ, and IDO2 
induction by PMA + A23187.  It may be too cumbersome to use a commercial 
tryptophan metabolism array such as the one I used, but perhaps select genes 
associated with mitochondrial function would be appropriate.  
 The cause of ASD is not known and likely involves interactions between 
genetic factors and environmental factors.  Previous articles have shown that 
there is a link between an over-expression of IL-6 and increased severity in ASD 
symptoms. IL-6 is ordinarily expressed at reasonably low levels in the brain, but 
in the presence of injury or inflammation, IL-6 is elevated in spinal fluid as well as 
brain homogenates [74].  In a study done by Wei, H. et al., it was shown that 
chronic overexpression of IL-6 in mice causes anatomical and physiological 
changes in the brain, leading to disorders such as ASD.  IL-10 is a well-known 
anti-inflammatory cytokine, and increased levels could point to a negative 
feedback loop type process. As levels of IL-6 increase, levels of IL-10 increase to 
try and lower IL-6. In this study, levels of IL-6 and IL-10 in non-stimulated 
lymphoblasts were observed.  It seems as though IL-6 levels are lowest in B26 
and the parents of B26, and perhaps because IL-10 helps to blunt inflammation, 




Typically, many children with ASD are not diagnosed until the age of 2 or 
3, meaning that the window to intervene early is essentially closed before a 
diagnosis is even made [61]. Even then, diagnosis depends on parent 
questioning, and seems subjective. As mentioned before, B26, the severely 
autistic child, has abnormalities on chromosome 10 and 15, both inherited from 
the parents Y17 and VT8. It is important to note that although Y17 (mother) has 
not been placed on the the autism spectrum, she had very similar responses to 
tryptophan as B26 (the child), as seen in the IL-6 and IL-10 figures. All of these 
data may point to more than a genetic association between specific 
chromosomal deletions and ASD. It was previously mentioned that there are 
thousands of submicroscopic structural variants covering up to roughly 18% of 
the human reference DNA sequence, which means that no one micro deletion or 
duplication points to ASD. It does mean, though, that there could be a possible 
way to diagnose ASD with genetic testing when the child is still very young, 
especially in families who have already had a child or children with ASD.  My 
assays and methods may be used in combination with analysis of genes involved 





 Moving forward from this study, a larger pool of study subjects 
(lymphoblast lines) would be beneficial, as there were only five subjects treated 
in this study. This would be especially helpful in performing another commercial 
amino acid array, or even RNAseq, as more cell lines would aide in possible links 
between these genes and severity of ASD. Although it was beneficial to have 
samples from the parents of B26, because it assisted in seeing a possible role of 
genetics in the development of ASD, it would have been more helpful to have 
more samples from patients with ASD of varying severity. As mentioned 
previously in this study, there was only one patient with severe ASD. ASD is a 
spectrum, as the name suggests, and being able to connect expression of genes 
and proteins of interest to the known severity of patients would have facilitated 
data to possibly be able to not only diagnose ASD with a simple blood test, but 
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Illustration 1 outlines the main intracellular pathways involving tryptophan, 

















Illustration 2 summaries the pathway of AhR-mediated transcription after 
binding. The AHR and ligand are displaced from the cytoplasm to the 
nucleus after binding, leading to transcription of both CYP1B1 and 








Some genes highly expressed by B26, and the mother, Y17 
Acetyl-CoA Acetyltransferase (ACAT1): This gene encodes an enzyme 
located in the mitochondria that catalyzes the reversible formation of acetoacetyl-
CoA from two molecules of acetyl-CoA. The ACAT enzyme is activated 
by potassium ions binding near the CoA binding site and the catalytic site. This 
binding causes a structural change in the active site loop. Additionally, this 
enzyme is able to use 2-methyl-branched acetoacetyl-CoA as a substrate, 
making it a unique thiolase. ACAT1 is regulated at both transcriptional and 
translational levels. ACAT1’s expression is promoted transcriptionally by leptin, 
angiotensin II, and insulin in human monocytes. Insulin-mediated regulation also 
involves ERK, p38MAPK, and JNK signaling pathways. 
 
Aralkylamine N-acetyltransferase (AANAT): The protein encoded by this gene 
belongs to the acetyltransferase superfamily. It is the penultimate enzyme 
in melatonin synthesis and controls the night/day rhythm in melatonin production 
in the vertebrate pineal gland. Melatonin is essential for the function of 
the circadian clock that influences activity and sleep. This enzyme is regulated 
by cAMP-dependent phosphorylation that promotes its interaction with 14-3-3 
proteins and thus protects the enzyme against proteasomal degradation.  




Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD): The 
neuronal excitotoxin quinolinate is an intermediate in the de novo synthesis 
pathway of NAD from tryptophan, and has been implicated in the pathogenesis of 
several neurodegenerative disorders. Quinolinate is derived from alpha-amino-
beta-carboxy-muconate-epsilon-semialdehyde (ACMS). ACMSD (ACMS 
decarboxylase; EC 4.1.1.45) can divert ACMS to a benign catabolite and thus 
prevent the accumulation of quinolinate from ACMS. 
 
4-trimethylaminobutyraldehyde Dehydrogenase (ALDH9A1): This protein 
belongs to the aldehyde dehydrogenase family of proteins. It has a high activity 
for oxidation of gamma-aminobutyraldehyde and other amino aldehydes. The 
enzyme catalyzes the dehydrogenation of gamma-aminobutyraldehyde to 
gamma-aminobutyric acid (GABA). This isozyme is a tetramer of identical 54-kD 
subunits.  
 
Enoyl-CoA Hydratase And 3-Hydroxyacyl CoA Dehydrogenase (EHHADH):  
his protein is involved in the pathway fatty acid beta-oxidation, which is part of 
Lipid metabolism. 
 
Amine Oxidase, Copper Containing 1 (AOC1): amine oxidase, copper 
containing 1.This gene encodes a metal-binding membrane glycoprotein that 




encoded protein is inhibited by amiloride, a diuretic that acts by closing epithelial 
sodium ion channels. Alternatively spliced transcript variants encoding multiple 
isoforms have been observed for this gene.  
 
Acyl-CoA Dehydrogenase Medium Chain (ACADM):  This enzyme is essential 
for converting these fatty acids to energy, especially during periods without food 
(fasting). The ACADM enzyme functions in mitochondria, the energy-producing 
centers within cells. It is found in the mitochondria of several types of tissues, 
particularly the liver. 
 
Aldehyde Dehydrogenase 18 Family Member A1 (ALDH18A1): Delta-1-
pyrroline-5-carboxylate synthetase (P5CS) is an enzyme that in humans is 
encoded by the ALDH18A1 gene. This gene is a member of the aldehyde 
dehydrogenase family and encodes a bifunctional ATP- and NADPH-
dependent mitochondrial enzyme with both gamma-glutamyl kinase and gamma 
glutamyl phosphatereductase activities. The encoded protein catalyzes the 
reduction of glutamate to delta1-pyrroline-5-carboxylate, a critical step in the de 
novo biosynthesis of proline, ornithine and arginine. Mutations in this gene lead 
to hyperammonemia, hypoornithinemia, hypocitrullinemia, hypoargininemia and 
hypoprolinemia and may be associated with neurodegeneration, cataracts, and 
connective tissue diseases. Alternatively spliced transcript variants, encoding 




Aldehyde Dehydrogenase 4 Family Member A1 (ALDH4A1): This protein 
belongs to the aldehyde dehydrogenase family of proteins. This enzyme is a 
mitochondrial matrix NAD-dependent dehydrogenase which catalyzes the 
second step of the proline degradation pathway, converting pyrroline-5-
carboxylate to glutamate. Deficiency of this enzyme is associated with type II 
hyperprolinemia, an autosomal recessive disorder characterized by accumulation 
of delta-1-pyrroline-5-carboxylate (P5C) and proline. Alternatively spliced 
transcript variants encoding different isoforms have been identified for this gene.  
 
Methylthioribulose 1-phosphate Dehydratase (APIP): Involved in 
the methionine salvage pathway. APIP deficiency is associated with cell 
death and cancer. 
 
Arginase 2 (ARG2):  Arginase catalyzes the hydrolysis of arginine to ornithine 
and urea. At least two isoforms of mammalian arginase exists (types I and II) 
which differ in their tissue distribution, subcellular localization, immunologic 
crossreactivity and physiologic function. The type II isoform encoded by this 
gene, is located in the mitochondria and expressed in extra-hepatic tissues, 
especially kidney. The physiologic role of this isoform is poorly understood; it is 
thought to play a role in nitric oxide and polyamine metabolism. Transcript 
variants of the type II gene resulting from the use of alternative polyadenylation 




Argininosuccinate Lyase (ASL): An enzyme that catalyzes the reversible 
breakdown of argininosuccinate (ASA) producing the amino acid arginine and 
dicarboxylic acid fumarate. Located in liver cytosol, ASL is the fourth enzyme of 
the urea cycle and involved in the biosynthesis of arginine in all species and the 
production of urea in ureotelicspecies. Mutations in ASL, resulting low activity of 
the enzyme, increase levels of urea in the body and result in various side effects. 
 
Argininosuccinate synthetase (ASS1): An enzyme that in humans is encoded 
by the ASS1 gene. The protein encoded by this gene catalyzes the penultimate 
step of the arginine biosynthetic pathway. There are approximately 10 to 14 
copies of this gene including the pseudogenes scattered across the human 
genome, among which the one located on chromosome 9 appears to be the only 
functional gene for argininosuccinate synthetase. Two transcript variants 
encoding the same protein have been found for this gene.  
 
3-methylglutaconyl-CoA hydratase (AUH): An enzyme encoded by 
the AUH gene on chromosome 19. It is a member of the enoyl-CoA 
hydratase/isomerase superfamily, but it is the only member of that family that is 
able to bind to RNA. Not only does it bind to RNA, AUH has also been observed 
to be involved in the metabolic enzymatic activity, making it a dual role protein. 
Mutations of this gene have been found to cause a disease called 3-




Branched Chain Amino Acid Transaminase 2 (BCAT2): This gene encodes a 
branched chain aminotransferase found in mitochondria. The encoded protein 
forms a dimer that catalyzes the first step in the production of the branched chain 
amino acids leucine, isoleucine, and valine. Multiple transcript variants encoding 
different isoforms have been found for this gene. 
 
Branched Chain Keto Acid Dehydrogenase E1, Alpha Polypeptide 
(BCKDHA): 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial is 
an enzyme that in humans is encoded by the BCKDHA gene. The second major 
step in the catabolism of the branched-chain amino acids, isoleucine, leucine, 
and valine, is catalyzed by the branched-chain alpha-keto acid dehydrogenase 
complex (BCKD; EC 1.2.4.4), an inner-mitochondrial enzyme complex that 
consists of 3 catalytic components:  
 
Betaine-homocysteine S-methyltransferase (BHMT): This gene encodes a 
cytosolic enzyme that catalyzes the conversion of betaine and homocysteine to 
dimethylglycine and methionine, respectively. Defects in this gene could lead to 
hyperhomocysteinemia, but such a defect has not yet been observed.  
 
Carbamoyl-phosphate synthetase 2, Aspartate transcarbamylase, and 
Dihydroorotase (CAD): Trifunctional multi-domain enzyme involved in the first 




with cytosoliccarbamoylphosphate synthetase II which uses glutamine, carbon 
dioxide and ATP. This enzyme is inhibited by uridine triphosphate (feedback 
inhibition). 
 
Cystathionine-β-synthase (CBS): An enzyme (EC4.2.1.22) that in humans is 
encoded by the CBS gene. It catalyzes the first step of the transsulfuration 
pathway, from homocysteine to cystathionine: L-serine + L-homocysteine  L-
cystathionine + H2O. CBS uses the cofactor pyridoxal-phosphate (PLP) and can 
be allosterically regulated by effectors such as the ubiquitous cofactor S-
adenosyl-L-methionine (adoMet). This enzyme belongs to the family of lyases, to 
be specific, the hydro-lyases, which cleave carbon-oxygen bonds. CBS is a 
multidomain enzyme composed of an N-terminal enzymatic domain and two CBS 
domains. The CBS gene is the most common locus for mutations associated 
with homocystinuria.  
 
Carbamoyl-phosphate Synthase 1 (CPS1): The mitochondrial enzyme 
encoded by this gene catalyzes synthesis of carbamoyl phosphate from 
ammonia and bicarbonate. This reaction is the first committed step of the urea 
cycle, which is important in the removal of excess urea from cells. The encoded 
protein may also represent a core mitochondrial nucleoid protein. Three 
transcript variants encoding different isoforms have been found for this gene. The 




gene have been associated with carbamoyl phosphate synthetase deficiency, 
susceptibility to persistent pulmonary hypertension, and susceptibility to 
venoocclusive disease after bone marrow transplantation 
 
Cystathionine gamma-lyase (CTH): An enzyme which breaks 
down cystathionine into cysteine, α-ketobutyrate, and ammonia. Pyridoxal 
phosphate is a prosthetic group of this enzyme. Cystathionine gamma-lyase 
also catalyses the following elimination reactions: L-homoserine to form H2O, 
NH3 and 2-oxobutanoate; L-cystine, producing thiocysteine, pyruvate and NH3; L-
cysteine producing pyruvate, NH3 and H2S. In some bacteria and mammals, 
including humans, this enzyme takes part in generating hydrogen sulfide. 
Hydrogen sulfide is one of a few gases that was recently discovered to have a 
role in cell signaling in the body.  
 
β2 microglobulin (B2M):  A component of MHC class I molecules, which are 
present on all nucleated cells (excludes red blood cells). In humans, the 
β2 microglobulin protein is encoded by the B2M gene.  
 
